Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2006 by Goupe d'Etudes et de Recherche Clinique En Rhumatologie.
Recruitment status was  Recruiting
Information provided by:
Goupe d'Etudes et de Recherche Clinique En Rhumatologie Identifier:
First received: February 14, 2006
Last updated: NA
Last verified: February 2006
History: No changes posted
Evaluation of two treatment modalities in early potentially severe early arthritis ( Methotrexate alone or in combination with adalimumab)

Condition Intervention Phase
Rheumatoid Arthritis
Drug: Adalimumab
Drug: Methotrexate
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Methotrexate Alone Versus Methotrexate in Combination With Adalimumab in Early Arthritis

Resource links provided by NLM:

Further study details as provided by Goupe d'Etudes et de Recherche Clinique En Rhumatologie:

Primary Outcome Measures:
  • Disease Activity Score

Secondary Outcome Measures:
  • -Radiological score
  • -Functional impairment ( HAQ)
  • -Pain (VAS)

Estimated Enrollment: 80
Study Start Date: May 2004
Estimated Study Completion Date: March 2007
Detailed Description:
Patients: early ( less than 6 months), active ( DAS>5.2),potentially severe ( Leiden score>6) Study design:12 months, prospective , randomized, open Study treatments: Methotrexate at a weekly dose of 0.3mg/kilo alone or in combination with adalimumab 40 mg every the other week Outcome measures: DAS over the 12 months

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Early Active Potentially severe arthritis

Exclusion Criteria:

  • contra indication of methotrexate or anti TNF
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00291915

Contact: Maxime r DOUGADOS, MD 00 33 1 58 41 25 62
Contact: Martin SOUBRIER, MD 00 33 6 81 74 78 85

Hopital Cochin Recruiting
Paris, France, 75014
Contact: Maxime DOUGADOS, md    00 33 1 58 41 25 62   
Contact: Martin SOUBRIER, MD    00 33 6 81 74 78 85    msoubrier@chu-clermond   
Principal Investigator: maxime DOUGADOS, MD         
Sub-Investigator: Martin SOUBRIER         
Sub-Investigator: Bernard COMBE, MD         
Sub-Investigator: Jean SIBILIA, MD         
Sub-Investigator: Olivier MEYER, MD         
Sub-Investigator: Xavier PUECHAL, MD         
Sub-Investigator: Françis BERENBAUM, PhD         
Sub-Investigator: Xavier MARIETTE, MD         
Sub-Investigator: Patrice FARDELLONE, MD         
Sub-Investigator: René Marc FLIPO, MD         
Sub-Investigator: Philippe GOUPILLE, PhD         
Sub-Investigator: Thierry SCHAEVERBEKE, PhD         
Sub-Investigator: C ZARNITSKY, MD         
Sponsors and Collaborators
Goupe d'Etudes et de Recherche Clinique En Rhumatologie
Principal Investigator: Maxime DOUGADOS, MD Hopital Cochin Paris FRance
  More Information Identifier: NCT00291915     History of Changes
Other Study ID Numbers: GUEPARD-GERCER 2122 
Study First Received: February 14, 2006
Last Updated: February 14, 2006
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Goupe d'Etudes et de Recherche Clinique En Rhumatologie:
early arthritis, methotrexate, adalimumab

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Anti-Inflammatory Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Physiological Effects of Drugs
Reproductive Control Agents processed this record on May 26, 2016